Lupin receives tentative USFDA approval for Fosaprepitant for Injection

07 May 2019 Evaluate

Lupin has received tentative approval for its Fosaprepitant for Injection, 150 mg Single-Dose Vial, from the United States Food and Drug Administration (USFDA) to market a generic version of Emend for Injection, 150 mg Single-Dose Vial, of Merck Sharp & Dohme Corp. (Merck).

Lupin's Fosaprepitant for Injection, 150 mg Single-Dose Vial, is the generic version of Merck's Emend for Injection, 150 mg Single-Dose Vial.

Fosaprepitant for Injection, 150 mg Single-Dose Vial, had annual sales of approximately $312 million in the US (IQVIA MAT March 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2176.25 -18.75 (-0.85%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×